From Code
to Cure
Therapeutic product discovery
In the information age
The next wave in immuno-oncology

NEWS

ALL NEWS

DISCOVERY

Holon

Our optimized process for predictive discovery of novel drug targets
READ MORE

DEVELOPMENT

San Francisco

Discovery & development of first-in-class monoclonal antibody therapeutics
READ MORE
Media coverage alt text

Our Pipeline

COM701/PVRIG (CGEN-15029)

CGEN-15029 is the internal designation for PVRIG, a novel B7/CD28-like immune checkpoint target candidate discovered by...
READ MORE

COM902/TIGIT (CGEN-15137)

CGEN-15137 is the internal designation for TIGIT, an immune checkpoint in the B7/CD28 family which has recently gained broad...
READ MORE

CGEN-15001T

CGEN-15001T is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15001T is expressed in various subpopulations of immune cells...
READ MORE

CGEN-15022

CGEN-15022 is a novel B7/CD28-like immune checkpoint target candidate discovered by Compugen. CGEN-15022 is expressed in numerous types of epithelial cancers, such...
READ MORE

CGEN-15001

CGEN-15001 is our lead program for autoimmune diseases. It is a first-in-class therapeutic candidate of a novel inhibitory checkpoint pathway, with the potential to restore...
READ MORE
Jul 24, 2017

Compugen to Present at ISMB/ECCB 2017

Prague, Czech Republic
MORE EVENTS

Collaborations

In August 2013, Compugen entered into a collaboration and license agreement with Bayer HealthCare ...
Click here for more info about partnering with Compugen